A Randomized Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 Delivered by Alternate Mucosal Routes in HIV-1 Uninfected Adult Volunteers
This study has been completed.
Study NCT00000884
Information provided by National Institute of Allergy and Infectious Diseases (NIAID)
First Received on November 2, 1999.
Last Updated on May 16, 2012
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
